Literature DB >> 17507239

Optimized expression from a synthetic gene of an untagged RNase H domain of human hepatitis B virus polymerase which is enzymatically active.

Nicoletta Potenza1, Vincenzo Salvatore, Domenico Raimondo, Davide Falanga, Valentina Nobile, Darrel L Peterson, Aniello Russo.   

Abstract

The RNase H domain of human hepatitis B virus (HBV) polymerase is an attractive molecular target for the development of new anti-HBV drugs. In this study, a synthetic gene coding for HBV RNase H was assembled from 12 oligonucleotides and expressed in Escherichia coli. The encoded protein was then recovered from inclusion bodies, purified, and refolded by a dilution-dialysis procedure in the presence of a low concentration of lauroylsarcosine (0.01%). The presence of the detergent was an absolute requirement for solubility, suggesting that the untagged RNase H might have exposed hydrophobic regions that need to be shielded from the solvent. The structural identity of the protein was confirmed by N-terminal amino acid sequence analysis and mass spectrometry. The enzymatic activity of HBV RNase H was then tested by a recently developed fluorometric assay and was found to be only slightly lower than that registered with the entire HIV-1 reverse transcriptase. Finally, a structural model of the enzyme showed that H715, R744 and K745 may be involved in substrate recognition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17507239     DOI: 10.1016/j.pep.2007.04.005

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  8 in total

1.  Ultradeep pyrosequencing and molecular modeling identify key structural features of hepatitis B virus RNase H, a putative target for antiviral intervention.

Authors:  Juliette Hayer; Christophe Rodriguez; Georgios Germanidis; Gilbert Deléage; Fabien Zoulim; Jean-Michel Pawlotsky; Christophe Combet
Journal:  J Virol       Date:  2013-10-30       Impact factor: 5.103

2.  Purification and enzymatic characterization of the hepatitis B virus ribonuclease H, a new target for antiviral inhibitors.

Authors:  Juan Antonio Villa; Daniel P Pike; Kunjan B Patel; Elena Lomonosova; Gaofeng Lu; Roz Abdulqader; John E Tavis
Journal:  Antiviral Res       Date:  2016-06-17       Impact factor: 5.970

3.  Large-scale production and structural and biophysical characterizations of the human hepatitis B virus polymerase.

Authors:  Judit Vörös; Annika Urbanek; Gilles Jean Philippe Rautureau; Maggie O'Connor; Henry C Fisher; Alison E Ashcroft; Neil Ferguson
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

Review 4.  The hepatitis B virus ribonuclease H as a drug target.

Authors:  John E Tavis; Elena Lomonosova
Journal:  Antiviral Res       Date:  2015-04-08       Impact factor: 5.970

5.  Functional characterization of human cytochrome P450 2S1 using a synthetic gene-expressed protein in Escherichia coli.

Authors:  Peter H Bui; Oliver Hankinson
Journal:  Mol Pharmacol       Date:  2009-08-27       Impact factor: 4.436

6.  An interdomain RNA binding site on the hepadnaviral polymerase that is essential for reverse transcription.

Authors:  Matthew P Badtke; Irfan Khan; Feng Cao; Jianming Hu; John E Tavis
Journal:  Virology       Date:  2009-05-24       Impact factor: 3.616

7.  Discovery and Selection of Hepatitis B Virus-Derived T Cell Epitopes for Global Immunotherapy Based on Viral Indispensability, Conservation, and HLA-Binding Strength.

Authors:  Monique T A de Beijer; Diahann T S L Jansen; Yingying Dou; Wim J E van Esch; Juk Yee Mok; Mariëlle J P Maas; Giso Brasser; Robert A de Man; Andrea M Woltman; Sonja I Buschow
Journal:  J Virol       Date:  2020-03-17       Impact factor: 5.103

8.  The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes.

Authors:  John E Tavis; Xiaohong Cheng; Yuan Hu; Michael Totten; Feng Cao; Eleftherios Michailidis; Rajeev Aurora; Marvin J Meyers; E Jon Jacobsen; Michael A Parniak; Stefan G Sarafianos
Journal:  PLoS Pathog       Date:  2013-01-22       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.